Drug news
IQWiG rejects Eylea for treatment of "wet" Age Related Macular Degeneration
Germany's Institute for Quality and Efficiency in Health Care (IQWiG) reported in a preliminary benefit assessment that Eylea (aflibercept) from BayerHealthCare has "no additional benefit" over Lucentis(ranibizumab), the comparator requested by Germany's Federal Joint Committee (G-BA) to treat wet age-related macular degeneration (AMD). The institute said the data Bayer submitted comparing Eylea and Lucentis were "not suitable" because Lucentis was not administered according to its European label.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.